Contact Information: For more information contact: Dawn Van Zant: 800-665-0411
Sector Close Up: Pharmaceutical and Biotech Stocks -- Is Gene Therapy the Next Major Breakthrough in Cancer Treatment?
POINT ROBERTS, WA and DELTA, BC--(Marketwire - October 22, 2007) - InvestorIdeas.com, a
leading online global investor resource, issues the Sector Close Up --
Pharmaceutical and Biotech Stocks. Gene therapy, which entails the
introduction of genetic material into a person's cells to fight or prevent
disease, is a highly promising area but one that is long on theory and
short on commercial product.
Benda
Pharmaceutical, Inc. (OTCBB : BPMA ) is a China-based pharmaceutical
company that has become recognized for its cancer gene therapy treatment
Gendicine®, which represents the world's first gene therapy medicine on
the market for the treatment of cancer. Gendicine® has been used to treat
more than 50 types of malignant tumors across 6,000 patients, including
more than 1,800 foreigners. According to the Company, in clinical trials on
135 patients affected by head and neck tumors, 64% had their tumors
eliminated after one month of Gendicine® treatment -- a 340% increase in
efficacy relative to traditional treatments.
According to Justin Davis from After Market Support, LLC, North American
representatives for Benda Pharmaceutical, "The addition of Gendicine® to
Benda's drug portfolio thrusts the Company to the leading edge of both the
gene therapy revolution and the world's ongoing fight against cancer. As
the first cancer-treating gene therapy drug available to the public --
anywhere -- Gendicine® has garnered international attention and has
turned both the medical and investing spotlights directly on Benda.
Moreover, the demonstrated efficacy of Gendicine® has already translated
into immediate financial returns for Benda -- $3.8 MM in orders in one day
after a recent medical conference in China. With the Company preparing to
present the latest independent findings to an international gene therapy
symposium in Europe, Benda finds itself at the cusp of what could become a
global phenomenon."
Another player in the gene therapy arena is Introgen Therapeutics, Inc. (Chart), a
biopharmaceutical company focused on targeted molecular therapies for the
treatment of cancer and other diseases. Introgen's gene therapy drug
ADVEXIN® has not yet been approved -- it is currently in Phase 3 clinical
trials for the treatment of head and neck cancer and Li-Fraumeni Syndrome.
According to the Company, regulatory filings in both the United States and
in Europe are expected to be completed by the end of 2007.
Sector Close Up -- Cancer Treatment Plays
Delcath Systems, Inc. (Chart), developer of
technology for targeted delivery of therapeutic and chemotherapeutic
agents, recently announced that its Phase III trial was approved by the
U.S. Food and Drug Administration under a Fast Track designation. Despite
this progress, the Company has seen its shares drop more than a dollar
since mid-September to its current level of $2.87.
Cell Genesys, Inc. (Chart), currently
conducting Phase 3 trials of the Company's GVAX™ immunotherapy for
prostate cancer, has rebounded slightly since early August's share price of
$3.22, closing Friday at $3.41.
Benda
Pharmaceutical, Inc. (OTCBB : BPMA ), on forecasts for 2008 of over $20
million in revenue from the Company's cancer treatment Gendicine®, has
been trading between $2.20-$2.49 over the past few weeks, up from the $0.70
level at which it began trading under one year ago.
Introgen Therapeutics, Inc. (Chart) has seen its share
price move from $3.16 at the beginning of August, to its recent close of
$4.02, an increase of approximately 27%.
At the beginning of 2006, pharmaceutical giant, Pfizer (Chart), received FDA approval
for Sutent® for the treatment of rare forms of intestinal and kidney
cancers. Sutent® is currently in trials for the treatment of breast,
lung, and colorectal cancer. Pfizer shares closed recently at $24.07.
Since mid-August, Bristol-Myers Squibb (Chart) shares have risen
approximately 5% and ImClone (Chart) has seen dramatic
results, up $13.48 in the same time period, based on Friday's close. Both
companies have recently found themselves in the spotlight after an
announcement that an agreement has been formed with Merck KGaA to
co-develop and co-market the cancer treatment Erbitux® in Japan.
Showcase Pharmaceutical Company:
Benda
Pharmaceutical Inc. (OTCBB : BPMA ), a China-based pharmaceutical
company, is a pure play on explosive Chinese pharmaceutical spending and
the global search for a cancer cure. For more info visit:
http://www.investorideas.com/co/bpma/
Compensation is disclosed in disclaimer below.
About InvestorIdeas.com
InvestorIdeas.com is a leading global investor and industry research
resource portal specialized in sector investing covering over thirty
industry sectors and global markets including China, India, Middle East and
Australia.
InvestorIdeas.com Disclaimer: www.InvestorIdeas.
com/About/Disclaimer.asp. Our sites do not make recommendations, but
offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. We attempt to research
thoroughly, but we offer no guarantees as to the accuracy of information
presented. All Information relating to featured companies is sourced from
public documents and/ or the company and is not the opinion of our web
sites. This site is currently compensated by featured companies, news
submissions and online advertising. Benda Pharmaceutical, Inc. (OTCBB : BPMA ) pays $4000USD per month. Benda Pharmaceutical, Inc. is also a client
of After Market Support, LLC.